Leman Biotech
LB
LE

Leman Biotech

Agent20Agent Readiness: 20/100. Bottom 25%. Measured by StartupHub.ai. Median 41.Speed81Site Speed: 81/100. Top 25%. Measured by Google PageSpeed. Median 62.

Clinical-stage biotech developing AI-driven metabolic immunotherapies for cancer and autoimmune diseases.

Website
2021InactiveShenzhen, China

About

Leman Biotech is a clinical-stage biotechnology company focused on developing next-generation cancer immunotherapies through metabolic reprogramming. Their proprietary META 10 platform aims to reverse T cell exhaustion, a key bottleneck in immunotherapy efficacy. The company leverages AI and metabolic reprogramming to create cell therapies with improved safety, efficacy, and accessibility.

Key facts

At-a-glance profile data

Website
lemanbiotech.com
Headquarters
Shenzhen, China
Founded
2021
Total funding
$23M (Series A)
Business model
B2B

Funding rounds

Funding rounds raised by Leman Biotech
DateRoundAmountLead investors
18 Jun 2024Series A$7M-
18 Jan 2022Seed$16M-
Add first review

Frequently asked

How much funding has Leman Biotech raised?

Leman Biotech has raised a total of $23M in funding. The most recent round on record is Series A.

What is Leman Biotech's current status?

Leman Biotech's current operating status is: Inactive.